Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

The Lancet
May 07, 2022 Volume 399 Number 10337 p1753-1844
https://www.thelancet.com/journals/lancet/issue/current

 

Articles
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
Sinead Delany-Moretlwe, et al.on behalf of the HPTN 084 study group
Open Access